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INTRODUCTION
Clonorchiasis is a liver fluke disease caused by Clonorchis si-
nensis in East Asia. It is estimated that about 30 millions of in­
fected population live in endemic areas [1]. Its prevalence is 
still high in Korea along endemic riversides although praziqu­
antel (PZQ) has been widely used [2]. The last 7th national sur­
vey revealed 2.9% prevalence of general population in 2004 in 
Korea. 
PZQ is known to be very effective and the drug of choice aga­
inst clonorchiasis by 3 divided doses, but a small part of medi­
cated patients, 14­17% of them, are not completely cured [3,4]. 
This incomplete cure is regarded as not a drug resistance but 
an outcome by individual variation of PZQ pharmacokinetics 
[5]. Because of rapid absorption and short half­life in human 
body, PZQ is recommended to use 3 times for medication of 
liver fluke diseases. Its cure rate for schistosomiasis is also known 
to be 60% to 80%, and the blood concentration of PZQ varies 
remarkably by individuals [6]. Therefore, individual variation 
of pharmacokinetics of PZQ may be important for the medi­
cation efficacy and cure of fluke infection.
Cytochrome P450 (CYP450) is a microsomal enzyme com­
plex, which metabolizes endogenous or exogenous compounds, 
including drugs and toxic chemicals, leading to their easy eli­
mination from human body. Two major isoenzymes, CYP2B1 
and CYP3A5, are mainly involved in hydroxylation of PZQ in 
the liver [6]. Mainly the hydroxy­PZQ in bile keeps the cidal 
activity on the liver fluke [5]. Among several isoenzyme genes, 
CYP3A5 has been known to be highly polymorphic and vari­
able by races [7,8]. Polymorphisms of CYP3A5 are suggested 
to contribute to individual and interracial differences in CY-
P3A5­dependent drug metabolism [8].
In this context, a hypothesis was proposed that cure of clo­
norchiasis by PZQ is correlated with pharmacokinetic variation 
which is determined by genetic polymorphisms of CYP450. 
The present study investigated the correlation between cure of 
clonorchiasis by PZQ and genetic variation of CYP3A5. 
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Abstract: Chemotherapy of clonorchiasis with praziquantel (PZQ) is effective but about 15% of treated cases have been 
reported uncured. The present study investigated correlation of single nucleotide polymorphisms (SNPs) of the cytoch­
rome P450 gene, CYP3A5 and cure of clonorchiasis. A total of 346 egg passing residents were subjected and treated by 
3 doses of 25 mg/kg PZQ. Reexamination recognized 33 (9.5%) uncured and 313 cured. Numbers of eggs per gram of 
feces (EPGs) before treatment were significantly lower in the cured group than in the uncured group (2,011. 2 ± 3,600.0 vs 
4,998.5±7,012.0, P<0.001). DNAs of the subjects were screened for SNPs at 7 locations of CYP3A5 using PCR. In the 
uncured group, the SNP frequencies at g.­20555G>A and g.27526C>T of CYP3A5 were 15.2% and 9.1% while those 
were 3.8% and 1.0%, respectively, in the cured group. The cure rate was significantly lower in the cases with SNP at 
g.27526C>T and EPGs≥1,000. In conclusion, EPGs and SNPs of CYP3A5 are factors which influence cure of clonorchi­
asis by PZQ therapy. It is strongly suggested to recommend 2­day medication for individuals with high EPGs≥1,000.
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MATERIALS AND METHODS
Subjected population
A total of 491 residents were recruited at a village in Hei­
longjiang, China, where clonorchiasis was hyperendemic [9]. 
They were 253 males and 238 females, age range 9­82 and 
median 40, and most of them were included partly in a sono­
graphic study [10]. They were examined of their feces for eggs 
of C. sinensis and their blood samples were collected in Sep­
tember 2004. Of them, 346 were egg positive and medicated 
with PZQ 25 mg/kg, ×3. They were reexamined 3 weeks after 
medication and divided into 2 groups, cured or uncured. The 
residents included in this study were informed and agreed with 
this study by oral communication.
Fecal examination 
The fecal specimens were examined by single smear of the 
Kato­Katz method [11]. The number of eggs on a smear was 
counted to estimate numbers of eggs per gram of feces (EPGs).
Single nucleotide polymorphisms (SNPs) of CYP3A5
Three drops of blood were spotted on filter paper and dried 
at room temperature. The blood spots were put into a 2­ml 
tube with a screw cap, and dissolved in 200 μl of 5% Chelex­ 
100 resin (Bio­Rad, Hercules, California, USA). Elution at 60˚C 
for 30 min and boiling at 100˚C for 30 min were carried out, 
and DNAs were obtained from the supernatant after centrifu­
gation. The tubes were subsequently centrifuged again for 10 
min at high speed to separate the surface layer in which the 
DNA can be found. The DNAs were stored at ­70˚C and used 
for the analysis.
Total 7 primer pairs were designed using known sequences 
within and upstream of CYP3A5 subfamily as previously de­
scribed (Table 1) [12,13]. Individual DNAs were used for tem­
plates and amplified with the primers by PCR under condition 
of initial denaturation at 94˚C 5 min, 94˚C 30 sec, 55­60˚C 30 
sec, and 72˚C 1 min for 35 cycles, and final extension at 72˚C 
for 10 min. The amplified fragments were sequenced by capil­
lary electrophoresis method using an automatic sequencer, ABI 
3730 DNA analyzer (Applied Biosystems, Branchburg, New 
Jersey, USA). The sequences were analyzed of SNPs using the 
program of DNASTAR (DNAStar Inc, Madison, Wisconsin, 
USA). 
 
Statistical analysis
The program SPSS (version 12.0) was used for statistical anal­
ysis. The data were summarized as mean±standard deviation 
or percentage proportion. Statistical significance of age and 
EPGs between groups was checked by Student’s t­test and that 
of gender, variation of SNPs was by chi­square analysis. Multi­
ple regression analysis was also applied to analyze the impact 
of age, gender, EPGs, and SNPs on cure of clonorchiasis. P val­
ues less than 0.05 were accepted as significant.
RESULTS
Primary fecal examination of the subjects
Of the 491 subjects, 346 were egg positive of C. sinensis (Ta­
ble 2). Their mean EPGs was 2,296.2±4,129.5, and 41.5% of 
them were under EPG 100, 27.5% 100­999, and 31%≥1,000.
The 346 egg positive subjects were examined again 3 weeks 
after PZQ medication by the same method. Of them, 313 (90.5%) 
Table 1. Sequences of primers of CYP3A5 gene
Primers Sequences
PS
a 2-1 Forward primer 5´-ACAGGCACAGAAACCCACAAG-3´
Reverse primer 5´-ATCGCCACTTGCCTTCTTC-3´
PS 2-2 Forward primer 5´-CCCTGCTTCGGCTTGTGCA-3´
Reverse primer 5´-CCTCTTCACAGCCTGCTTTATTTGTCA-3´
Exon 1-6 Forward primer 5´-GCCGAGACGCACCATTACACT-3´
Reverse primer 5´-ATGAGTGGGAAGGGATGGGTG-3´
Exon 1-11 Forward primer   5´-CACTCCAATATTCACAATAGCCAC-
TATTCA-3´
Reverse primer 5´-ACTCCTACGTATCCTTCCAAGCCC-3´
Exon 10 Forward primer 5´-TCCTTCTCCAGCACATAAATC-3´
Reverse primer 5´-AAATTAGAAGGTGGATGGGAG-3´
Intron 11 Forward primer 5´-GACATCTCTGAATAGCTTCCTTC-3´
Reverse primer 5´-GCACATAGTTTATAACGGCAA-3´
Exon 13 Forward primer 5´-AAATACTTCACGAATACTATGATCA-3´
Reverse primer 5´-CAGGGACATAATTGATTATCTTTG-3´
apromoter site.
The primers were designed according to Chou et al. (2001) [12].
Table 2. Demographic characteristics of subjects and results of 
fecal examination
C. sinensis
egg+
(n=346)
C. sinensis
egg-
(n=145)
Total
(n=491)
P-value
Age (years) 40.3±12.9
a 37.1±14.6 39.3±13.5    0.022
Sex, n (%) 
   Male 179 (51.7) 74 (51.0) 253 (51.5)    0.483
   Female 167 (48.3) 71 (49.0) 238 (48.5)
EPGs  2,296.2±4,129.5  0 1,618.1±3,620.2 <0.001
aMean±SD.  Kim et al.: Infection burden and CYP3A5 gene polymorphism on cure of clonorchiasis by praziquantel   47
were converted to negative and 33 were still positive (Table 3). 
Age and gender differences were not significant between the 
cured and uncured groups, but EPGs, 2,011.2±3,600.0 in cured 
and 4,998.5±7,012.0 in uncured, differed significantly (P< 
0.001).
SNP frequency of CYP3A5 
Among the 7 sites of the CYP3A5 gene: g.­20619T>G, g.­
20555G>A, g.­6177A>G, g.­795T>A, g.19386G>A, g.27526C>T, 
and g.31611T>C, g.­20555G>A showed the most frequent vari­
ation, 17 (4.9%) of 346, and the second was g.­6177A>G, 3.5%. 
The frequencies were 1.7%­2.3% in other sites (Table 4). 
SNPs of CYP3A5 and cure rates 
Significant difference of SNP frequency between the cured 
and uncured groups was recognized in location of g.­20555G>A 
(Po=0.016) and g.27526C>T (P=0.013). SNP variant of g.­
20555G>A was 3.8% in cured group but 15.2% in uncured 
group, and that of g.27526C>T was 1.0% and 9.1%, respec­
tively (Table 4). No significant difference was found in other 
locations (Table 4).
Cure rates by EPGs 
Cure rates were significantly correlated with EPGs. In the 
group of EPGs less than 100, all of 59 (100%) treated subjects 
were cured while 123 (91.1%) and 131 (86.2%) were cured in 
groups of EPGs of 100­999 and ≥1,000, respectively (P=0.009).
Cure rates by SNP variation in groups of EPGs
Cure rates were compared by the 7 allelic locations of SNP 
variation by EPGs. The SNP frequencies of all locations showed 
no significant differences of cure rates in the group of EPGs 100­
999. However, g.27526C>T variants revealed a significantly low 
cure rate in the group of EPGs ≥1,000 (Table 5).
Multiple regression analysis 
All of observed variables were reviewed by multiple regres­
sion analysis (Table 6). Age and sex were not significant but 
EPGs (P=0.004) and SNPs at g.27526C>T (P=0.001) were 
significant with cure of clonorchiasis.
DISCUSSION
The present study investigated the hypothesis that cure of 
clonorchiasis by PZQ was determined by genetic polymorph­
ism of CYP3A5. The hypothesis was accepted because the pres­
ent findings confirmed that SNPs of g.27526C>T and EPGs≥ 
1,000 were significantly correlated.
When PZQ is introduced into the human body, it is absorb­
ed in the intestine, circulated in blood, metabolized in the liv­
er, and then excreted in urine or feces [5,6]. Metabolism of PZQ 
in the liver is most critical for cure of clonorchiasis because the 
cure mainly depends upon concentration of hydroxy­PZQ in 
bile [6]. Since PZQ concentration in blood is widely variable 
by individuals, its concentration in bile must be more variable 
due to the blood­bile barrier. That may be supposed the major 
Table 3. Demographic characteristics of clonorchiasis patients 
by praziquantel therapy
Parameters Cured
(n=313)
Uncured
(n=33)
Total 
(n=346)
P-value
Age (years) 40.0±12.9
a 42.6±13.6 40.3±12.9      0.298
Sex, n (%) 
   Male 163 (52.1) 16 (48.5) 179 (51.7)      0.417
   Female 150 (47.9) 17 (51.5) 167 (48.3)
EPGs 
   Pre-treatment 2,011.2± 
3,600.0
4,998.5± 
7,012.0 
2,296.2± 
4,129.5
<0.001
   Post-treatment 0 268.4± 222.1 25.6±104.0 <0.001
   E  gg reduction rate 
(%)
100 82.3±16.3 98.3±7.2 <0.001
aMean±SD.
Table 4. Frequencies of CYP3A5 SNPs by groups
Locations     Variants Sequences
Allelic frequencies (%)
P-value
Cured (n=313) Uncured (n=33) Total (n=346)
PS 2-1 g.-20619T>G TGGGCTTGCAA. . . . . …G . . . . .  4 (1.3)
a 2 (6.1)  6 (1.7) 0.104
PS 2-2 g.-20555G>A GCATGGGTAAA. . . . . .A . . . . .  12 (3.8)  5 (15.2)  17 (4.9) 0.016
Exon 1-6 g.-6177A>G CTCACACTGGG. . . . . …G . . . . .  9 (2.9)  3 (9.1)  12 (3.5) 0.096
Exon 1-11 g.-795T>A  TCTATTGCTAT. . . . . A . . . . .  5 (1.6) 1 (3.0)  6 (1.7) 0.454
Exon 10 g.19386G>A TTGATGCAGTT. . . . . …A . . . . .  7 (2.2) 1 (3.0)  8 (2.3) 0.555
Intron 11 g.27526C>T CGAAACTACAT. . . . . ….T . . . . .  3 (1.0) 3 (9.1)  6 (1.7) 0.013
Exon 13 g.31611T>C  AAGGATTTCTA. . . . . ….C . . . . .  5 (1.6) 2 (6.1)  7 (2.0) 0.137
an (%).48   Korean J Parasitol. Vol. 49, No. 1: 45­49, March 2011
reason of incomplete cure of clonorchiasis by single PZQ med­
ication.
CYP3A5, which determines activity of hydroxylation of PZQ, 
is known variable by ethnics. SNP at intron 3 (g.6986A>G; 
CYP3A5*3) was found 88% among Caucasians but 35% in 
Africans [7]. Roy et al. [8] recorded SNPs of CYP3A5 in 92.9%, 
77.6%, 70.0%, 27.0­50.0%, and 75% of Caucasians, Zimba­
bweans, Europeans, African Americans, and Asians, respective­
ly. The frequency of total SNPs of CYP3A5 at 7 locations was 
17.9% in the 346 Chinese subjects in this study. This rate was 
lower than those of previous reports [12]. The difference of 
SNPs is comparable only when same location is observed. There 
is one record of SNPs at same locations in Caucasians [13]. The 
SNP frequency was 7.1% and 7.0% in locations of g.­20619T 
>G and g.­6177A>G among Caucasians while the present study 
observed rates of 1.7% and 3.5%. The SNP frequency was much 
lower in the present study than that of Caucasians in several 
other locations.
The low SNP frequency of CYP3A5 is possibly contributing 
to high cure rates of PZQ therapy in Asians. The present cure 
rate was 90.5% of liver fluke disease in Chinese and higher than 
60­80% of blood fluke infection in Caucasians [6]. The differ­
ence is greatly meaningful because infection of liver flukes is 
more difficult to cure than that of blood flukes because of the 
blood­bile barrier [5].
The SNP frequencies of g.­20555G>A and g.27526C>T were 
15.2% and 9.1% in the uncured group while those of cured 
group were 3.8% and 1.0%. The difference was big enough to 
explain the outcome of PZQ therapy. In other words, it is in­
ferred that individuals with the SNPs of the 2 locations of CY-
P3A5 may have less concentration of hydroxy­PZQ in their 
bile. Although it is almost impossible to monitor concentra­
tion of hydroxy­PZQ in human bile, this inference is highly 
plausible. The location of g.27526C>T SNP was in the intron 
11, which was not translated. It is still uncertain to explain how 
untranslated SNPs may be involved in influencing enzyme ac­
tivities. However, it is presumed to influence stability of the ge­
ne during translation. This should be a topic of further studies.
One more correlated significant factor was EPGs of the sub­
jects. The subjects with more EPGs were less cured. EPG counts 
roughly estimate infection burden of flukes. Therefore, the high­
er the burden of the liver fluke, the lower the PZQ cure rates 
were. This phenomenon was suggested by good egg reduction 
rate (over 95%) of PZQ in clonorchiasis while its cure rate was 
near 85% [3,4]. Cure of clonorchiasis means complete elimi­
nation of flukes from the target human body. Therefore, cure 
Table 5. Frequencies of CYP3A5 SNPs by cure after praziquan-
tel therapy and EPG counts
EPGs 100-999 SNPs Cured  Uncured P-value
b
g.-20619T>G T 122 (99.2)
a 11 (91.7) 0.170
G 1 (0.8) 1 (8.3)
g.-20555G>A G 119 (96.7) 10 (83.3) 0.089
A  4 (3.3)  2 (16.7)
g.-6177A>G A 119 (96.7) 10 (83.3) 0.089
G  4 (3.3)  2 (16.7)
g.-795T>A  T 122 (99.2) 11 (91.7) 0.170
A  1 (0.8) 1 (8.3)
g.19386G>A G 122 (99.2) 11 (91.7) 0.170
A  1 (0.8) 1 (8.3)
g.27526C>T C 122 (99.2) 12 (100) 0.911
T  1 (0.8) 0 (0.0)
g.31611T>C  T 122 (99.2) 11 (91.7) 0.170
C  1 (0.8) 1 (8.3)
EPG ≥1,000 Variants Cured  Uncured P-value
b
g.-20619T>G T 127 (96.9)
a 20 (95.2) 0.530
G 4 (3.1) 1 (4.8)
g.-20555G>A G 128 (97.7) 20 (95.2) 0.452
A  3 (2.3) 1 (4.8)
g.-6177A>G A 123 (93.9) 18 (85.7) 0.180
G  8 (6.1)  3 (14.3)
g.-795T>A  T 127 (96.9) 21 (100) 0.548
A  4 (3.1) 0 (0.0)
g.19386G>A G 127 (96.9) 21 (100) 0.548
A  4 (3.1) 0 (0.0)
g.27526C>T C 129 (98.5) 18 (85.7) 0.019
T  2 (1.5)  3 (14.3)
g.31611T>C  T 127 (96.9)  20 (95.2) 0.530
C  4 (3.1)  1 (4.8)
an (%); 
bP values by chi-square test.
Table 6. Multiple regression coefficients between cure rates of 
clonorchiasis and related factors
Dependent variables EC
a SE
b t
c    P-value
d
Age 0.001 0.001 0.584 0.559
Sex 0.009 0.031 0.289 0.773
Pre-treatment EPGs  0.01 0.000 2.923 0.004
CYP3A5 SNPs
   g.-20619T>G 0.055 0.164 1.387 0.166
   g.-20555G>A 0.157 2.153 0.164 0.870
   g.-6177A>G 0.127 1.387 2.153 0.032
   g.-795T>A  -0.663 0.322 2.062 0.040
   g.19386G>A -0.038 0.111 -0.347 0.729
   g.27526C>T 0.388 0.118 3.288 0.001
   g.31611T>C  0.634 0.443 1.433 0.153
aEstimated coefficient; 
bStandard error of the estimated coefficient; 
ct sta-
tistics; 
dP value by multiple linear regression analysis.  Kim et al.: Infection burden and CYP3A5 gene polymorphism on cure of clonorchiasis by praziquantel   49
is less possible in individuals with high EPGs than those with 
low EPGs. Some flukes in humans with high EPGs may survive 
from PZQ therapy while most of them are eliminated from the 
body. Previous reports demonstrated that the uncured subjects 
were all cured by one more PZQ therapy [3,4]. In the present 
study also, all of the light burden individuals of EPGs less than 
100 were cured by one medication. The worm burden is a defi­
nite factor which reduces cure rates in clonorchiasis. In this po­
int of view, EPG count itself is more important than SNPs of 
CYP3A5 for cure.
The limitation of this study was the small number of uncured 
subjects. A total of 33 uncured individuals were included in 
this SNPs analysis. The frequencies of SNPs were low, and thus 
the numbers for analysis were very small. Another limitation 
of this study was no information of PZQ concentration in blood 
or bile. If those data were collected together, the present con­
clusion might have been more concrete.
In conclusion, both EPGs and SNPs of CYP3A5 are factors 
which influence cure of clonorchiasis by PZQ. It is suggested 
to recommend 2­day medication for clonorchiasis of individu­
als with higher EPGs than 1,000 for better cure because SNP 
analysis of CYP3A5 is not routinely investigated.
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